Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Stock Information for Aclarion Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aclarion Inc.

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Aclarion Provides 2025 Update and 2026 Corporate Outlook
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.